Eliglustat

Cat. No. M5610

All AbMole products are for research use only, cannot be used for human consumption.

Synonym:

GENZ-112638

Size	Price	Availability
5mg	USD 95	In stock
10mg	USD 130	In stock
25mg	USD 225	In stock
50mg	USD 315	In stock

Free Delivery on orders over USD 500 Bulk Inquiry?

Eliglustat inhibits glucosylceramide synthase (GCS), thus reducing the load of glucosylceramide influx into the lysosome.

BioRxiv. 2024 Apr 04;587899.

Vesicle-mediated mitochondrial clearance underlies an actionable metabolic vulnerability in triple-negative breast cancer
Eliglustat purchased from AbMole
Nat Commun. 2020 Aug 27;11(1):4279.

Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer
Eliglustat purchased from AbMole

	Source	Nat Commun (2020), Figure 7, Eliglustat (Abmole Bioscience Inc.)
	Method	intraperitoneal injection
	Cell Lines	C57Bl/6N mice
	Concentrations	60 mg/kg
	Incubation Time	15 days
	Results	Metabolomics analysis of tumor tissues from all treatment groups showed that eliglustat was linked to reductions in glycosphingolipids in RM-9 tumor bearing mice

Molecular Weight	404.54
Formula	C23H36N2O4
CAS Number	491833-29-5
Solubility (25°C)	DMSO ≥ 60 mg/mL
Storage	Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month

Related Glucosylceramide Synthase Products
Miglustat Miglustat(OGT918) is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).
Ibiglustat Ibiglustat (Venglustat) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor.
Miglustat hydrochloride Miglustat hydrochloride also known as OGT 918 and NB-DNJ, inhibits glucosylceramide synthase, and is used primarily to treat Type I Gaucher disease (GD1).

Catalog